Gary Nabors

Gary Nabors has a diverse and extensive work experience in the field of biotechnology and pharmaceuticals. Starting in 1991 at the University of Pennsylvania, they worked as a Postdoctoral Research Associate, focusing on the immunology of parasitic infections. Their research resulted in important findings on modifying immune responses for the treatment of leishmaniasis.

In 1995, Nabors joined Sanofi Pasteur as the Manager of Immunology. Here, they played a key role in the development of a protein-based vaccine for pneumococcal disease and was responsible for evaluating immune responses to vaccine candidates.

Moving on to Antex Biologics in 2001, they served as Director of Immunology. Their responsibilities included evaluating candidate vaccines in animal models and developing immune-based assays. Gary led or served on project teams for three vaccines under IND.

Nabors joined Emergent BioSolutions in 2003 and held various roles, including Director of Immunology and Vice President of Product Development. Gary managed a portfolio of clinical stage biodefense vaccines and therapeutics, with a focus on anthrax. Gary also played an advisory role for vaccines to prevent influenza and tuberculosis.

Gary then worked at BNBI as the Deputy Director of the National Biological Threat Characterization Center before taking on the role of President at DynPort Vaccine Company in 2014. As President, they oversaw the development of vaccines and therapeutics under contract to government agencies, including products for prevention and treatment of botulism and plague.

In 2020, Nabors became the Executive Vice President and Chief Development Officer at Integrated BioTherapeutics. This privately held company focuses on the discovery and development of vaccines and antibody therapeutics for emerging infectious diseases, with a lead product being a vaccine against Staphylococcus aureus.

Currently, Nabors holds the position of Chief Development Officer at Appili Therapeutics since 2023.

Throughout their career, Nabors has demonstrated expertise in vaccine and therapeutic development, clinical trials, and immunology research.

Gary Nabors has a Bachelor of Arts degree in Biology from Wake Forest University. Gary also holds a Ph.D. in Immunology from The University of Georgia. The specific start and end years for both degrees are not provided.